Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Reneuron Share Price
  4. Reneuron Share Regulatory News
  5. Initiation of research by Allenby Capital

Pin to quick picksReneuron Regulatory News (RENE)

Reneuron Information
  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Initiation of research by Allenby Capital

29 Apr 2021 07:00

RNS Number : 9643W
ReNeuron Group plc
29 April 2021
 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Initiation of research by Allenby Capital

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the initiation of research by Allenby Capital Limited, the Company's joint broker.

 

The research is available to view on the ReNeuron website here: http://www.reneuron.com/investors/analyst-research-and-presentations/

 

Contacts:

 

ReNeuron

www.reneuron.com/investors

Olav Hellebø, Chief Executive Officer

Via Walbrook PR

Michael Hunt, Chief Financial Officer

 

 

 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

 

 

 

Allenby Capital Limited (Joint Broker)

James Reeve/George Payne (Corporate Finance)

Tim Sohal (Sales & Corporate Broking)

+44 (0)20 3328 5656

  

Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus, Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

About ReNeuron

 

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEASLPALDFEFA
12345678910
Date   Source Headline
20th Oct 20217:00 amRNSDirector/PDMR Interest in Share Options
18th Oct 20217:00 amRNSFurther changes in the Board of Directors
18th Oct 20217:00 amRNSFirst subject treated at Oxford Eye Hospital
12th Oct 20212:05 pmRNSSecond Price Monitoring Extn
12th Oct 20212:01 pmRNSPrice Monitoring Extension
11th Oct 20214:40 pmRNSSecond Price Monitoring Extn
11th Oct 20214:35 pmRNSPrice Monitoring Extension
11th Oct 20212:06 pmRNSSecond Price Monitoring Extn
11th Oct 20212:00 pmRNSPrice Monitoring Extension
11th Oct 202111:05 amRNSSecond Price Monitoring Extn
11th Oct 202111:00 amRNSPrice Monitoring Extension
11th Oct 20219:05 amRNSSecond Price Monitoring Extn
11th Oct 20219:00 amRNSPrice Monitoring Extension
11th Oct 20217:00 amRNSPositive data generated in exosome collaboration
1st Oct 20217:00 amRNSRegulatory approval for continuation of RP trial
16th Sep 20214:26 pmRNSResult of AGM
2nd Sep 202112:00 pmRNSBlock Listing Review, Application and TVR
16th Aug 20212:20 pmRNSPosting of AR and Accounts and Notice of AGM
6th Aug 20217:00 amRNSDirectorate Change
14th Jul 20217:00 amRNSBoard Change
8th Jul 20217:00 amRNSPreliminary Results for the year ended 31 March 21
2nd Jul 20211:00 pmRNSNotice of Results
2nd Jul 20217:00 amRNSNotice of Results
1st Jul 20217:00 amRNSDirectorate Change
1st Jul 20217:00 amRNSTotal Voting Rights
18th Jun 202110:48 amRNSHolding(s) in Company
9th Jun 20214:36 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension
9th Jun 202111:55 amRNSUpdate for hRPC therapy candidate study
7th Jun 20215:25 pmRNSHolding(s) in Company
20th May 20217:00 amRNSAppointment of Chief Scientific Officer
4th May 20217:00 amRNSTotal Voting Rights
29th Apr 20217:00 amRNSInitiation of research by Allenby Capital
6th Apr 20217:00 amRNSVirtual conference attendance and presentations
30th Mar 20217:00 amRNSHolding(s) in Company
19th Mar 20217:00 amRNSExosome platform update
16th Mar 20214:05 pmRNSHolding(s) in Company
16th Mar 202110:57 amRNSHolding(s) in Company
16th Mar 20217:00 amRNSHolding(s) in Company
12th Mar 20217:00 amRNSDirectorate Change
1st Mar 20217:00 amRNSBlock Listing Review and Total Voting Rights
25th Feb 20217:01 amRNSInvestor presentations
25th Feb 20217:00 amRNSAppointment of Joint Broker
11th Feb 20217:00 amRNSDirector/PDMR Interest in Shares and Share Options
1st Feb 20219:55 amRNSTotal Voting Rights
15th Jan 20212:06 pmRNSSecond Price Monitoring Extn
15th Jan 20212:01 pmRNSPrice Monitoring Extension
15th Jan 20217:00 amRNSClinical Update
6th Jan 20217:00 amRNSAnalyst Conference Call
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.